Market Snapshot: C-Bridge Raises $400 Million For Second China Healthcare Fund


C-Bridge Capital, a China private equity firm with a life science focus, closed its second fund, C-Bridge Healthcare Fund II, at its $400 million cap. C-Bridge plans to invest in late-stage companies in the fields of biotechnology, pharmaceuticals, medical devices and health care, particularly those with cross-border ambitions. C-Bridge is active in Asia-Pacific – especially China – the US and Israel. Its first healthcare fund closed in 2014 after raising $200 million.

About China Med Device, LLC (CMD) CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at

Related Posts